Clinical Trial Update: Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease [Phase 1]

View source ↗

Summary

Phase 1 safety study of CAT-8015 (Immunoxin) in patients with advanced non-Hodgkin lymphoma and leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Immunoxin (CAT-8015)

Snippet

Sponsor: Cambridge Antibody Technology | Conditions: Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Status: UNKNOWN